Shree SSD Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Shree SSD Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $459.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Shree SSD Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $459.3K Trade | TransData Nexus

Shree SSD Pharma Private Limited

Indian Pharmaceutical Exporter · Advanced Diabetes Medications Specialist · $459.3K Total Trade · DGFT Verified

Shree SSD Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $459.3K across 4 products in 2 therapeutic categories. Based on 54 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Canagliflozin ($190.0K), Empagliflozin ($127.7K), Linagliptin ($127.6K).

Shree SSD Pharma Private Limited — Export Portfolio & Destination Treemap

Shree SSD Pharma Private Limited pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Shree SSD Pharma Private Limited? — Company Overview & Market Position

Shree SSD Pharma Private Limited, established on August 6, 2012, is a private limited company headquartered in Nagpur, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74120MH2012PTC234219. Its authorized and paid-up capital stands at ₹500,000 each. The registered office is located at 1st Floor, Shree SSD Heights, House No. 16, Besides Rajwada Palace, Ganjipeth, Nagpur, Maharashtra, 440002.

The company operates as a trader, wholesaler, and distributor in the pharmaceutical sector, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. As of the latest available data, Shree SSD Pharma employs up to 10 people and has an annual turnover ranging between ₹25 crore and ₹100 crore.

What Does Shree SSD Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Canagliflozin$190.0K 2Empagliflozin

Product Portfolio — Top 4 by Export Value

Shree SSD Pharma Private Limited exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Canagliflozin	Advanced Diabetes Medications	$190.0K	16	21.5%	2
2	Empagliflozin	Diabetes & Endocrine	$127.7K	17	1.9%	14
3	Linagliptin	Advanced Diabetes Medications	$127.6K	16	3.3%	3
4	Saxagliptin	Advanced Diabetes Medications	$13.9K	5	0.4%	4

Shree SSD Pharma Private Limited exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $459.3K. The top category is Advanced Diabetes Medications (72.2% of portfolio), followed by Diabetes & Endocrine (27.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Shree SSD Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Shree SSD Pharma Private Limited does not own manufacturing facilities; instead, it operates as a trader, wholesaler, and distributor of pharmaceutical products. The company sources its products from various manufacturers to cater to its export and domestic distribution needs. Specific details regarding the manufacturing capacities and specializations of its suppliers are not publicly disclosed.

3Key Leadership

The leadership team of Shree SSD Pharma Private Limited comprises four directors:

Shrichand Hundomal Daswani
Manish Shrichand Daswani
Jaiprakash Nandlal Tekchandani
Jagdish Shrichand Daswani

These directors have been associated with the company since its inception on August 6, 2012.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Shree SSD Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Shree SSD Pharma Private Limited's export data indicates a focus on advanced diabetes medications, including Canagliflozin, Empagliflozin, Linagliptin, and Saxagliptin. However, specific regulatory approvals or market access statuses in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's export activities primarily target markets where these products are in demand, but detailed regulatory information is not disclosed.

2Emerging Markets

Shree SSD Pharma Private Limited's export data does not provide specific information regarding its presence in African, Latin American, or Southeast Asian markets. The company's focus appears to be on regions with established demand for its product portfolio. Without explicit data on WHO prequalification or other certifications, it is challenging to assess the company's penetration in these emerging markets.

3Geographic Strategy

The company's export data reveals a concentrated portfolio, with the top five products accounting for 100% of its exports. This indicates a high level of concentration risk. Diversification into additional therapeutic categories or geographic regions could mitigate this risk and enhance the company's strategic position.

Shree SSD Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Shree SSD Pharma Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history is not publicly available. As the company operates as a trader and distributor, it is likely that its manufacturing partners hold the necessary FDA approvals for the products it exports.

2WHO & EU GMP

There is no publicly available information confirming whether Shree SSD Pharma Private Limited or its manufacturing partners hold WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. Such certifications are crucial for market access in various regions, and the absence of this information may impact the company's ability to enter certain markets.

3CDSCO & Indian Regulatory

Shree SSD Pharma Private Limited is registered with the Directorate General of Foreign Trade (DGFT) under the Import Export Code (IEC) 5012002652, indicating its authorization to export pharmaceutical products. Specific details regarding manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) or state drug controller approvals are not publicly disclosed.

Shree SSD Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Shree SSD Pharma Private Limited operates in a competitive pharmaceutical export market, focusing on advanced diabetes medications. While specific competitors are not identified, the company's concentrated product portfolio may limit its market share in comparison to competitors with diversified offerings. Expanding its product range and geographic reach could enhance its competitive position.

2Key Differentiators

The company's specialization in advanced diabetes medications, including Canagliflozin, Empagliflozin, Linagliptin, and Saxagliptin, positions it as a focused player in this therapeutic area. However, the lack of diversification in its product portfolio may limit its appeal to a broader customer base.

3Strategic Position

Shree SSD Pharma Private Limited's current strategic direction appears to be focused on exporting a limited range of advanced diabetes medications. To strengthen its market position, the company could consider diversifying its product portfolio, obtaining relevant certifications, and expanding into new geographic markets.

Buyer Due Diligence Brief — Evaluating Shree SSD Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

As a trader and distributor, Shree SSD Pharma Private Limited relies on its manufacturing partners for product quality and regulatory compliance. The company's export data indicates a focus on high-demand products, suggesting a consistent supply chain. However, the lack of publicly available information on supplier certifications and compliance histories makes it challenging to fully assess the reliability of its suppliers.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the manufacturing facility holds FDA approval for the specific products. Verification can be done through the FDA's official website.

WHO-GMP: Ensure that the manufacturing facility complies with WHO Good Manufacturing Practices. Verification can be done through the WHO's official website.

Frequently Asked Questions — Shree SSD Pharma Private Limited

How many pharmaceutical products does Shree SSD Pharma Private Limited export from India?

Shree SSD Pharma Private Limited exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Canagliflozin ($190.0K), Empagliflozin ($127.7K), Linagliptin ($127.6K), Saxagliptin ($13.9K). Total export value is $459.3K.

What is Shree SSD Pharma Private Limited's total pharmaceutical export value?

Shree SSD Pharma Private Limited's total pharmaceutical export value is $459.3K, based on 54 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Shree SSD Pharma Private Limited cover?

Shree SSD Pharma Private Limited exports across 2 therapeutic categories. The largest are Advanced Diabetes Medications (72.2%, 3 products), Diabetes & Endocrine (27.8%, 1 products).

Get Full Shree SSD Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.